Jung 2007.

Methods	A open‐label cohort study of osmotic release oral system (OROS) methylphenidate use for 4 weeks
Participants	Number of participants screened: not stated Number of participants included: 91 Number of participants followed up: 83 Number of withdrawals: 8 Diagnosis of ADHD: DSM‐IV (subtype: 100% combined) Age: mean 8.46, range: 6‐12 years old IQ: mean 96 (SD 15.17). All above 70 Sex: 75 males, (90.4%), 8 females Methylphenidate‐naïve: not stated Ethnicity: not stated Country: Korea Comorbidity: not stated Sociodemographics: not stated Inclusion criteria ADHD combined subtype Maternal report of development history consistent with ADHD Exclusion criteria IQ below 70 Gross neurological, sensory or motor impairment as determined by paediatric examinations Comorbid diagnosis as: seizure, psychosis, Tourette's syndrome, mental retardation, cardiovascular disorder, thyroid disorder, drug abuse history, intestinal obstruction ADHD treatment drugs, herbs, antidepressants, antipsychotics within 1 month of the study Taking OROS methylphenidate less than 2 days a week during study period
Interventions	Methylphenidate type: osmotic release oral system (extended release) Methylphenidate dosage: start dosage was 18 or 36 mg based on the clinician's judgment and dosage was adjusted at each visit if necessary Administration schedule: once per day in the morning before 8:30 Duration of intervention: 4 weeks Treatment compliance: not stated
Outcomes	Non‐serious adverse events: 79.5% showed ≥ 1 harmful effects of medication with most being mild. Not mentioned how these were measured
Notes	Sample calculation: no Ethics approval: yes Funding/vested interests: Janssen Korea Pharmaceuticals LTD Key conclusions of the study authors: OROS methylphenidate improves performance on common tests of cognitive function. A further long‐term follow‐up study of these effects in ADHD is warranted Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: no